Psilocybin for the treatment of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review describing theoretical mechanisms and preclinical rationale without original empirical clinical data.
PubMed 39050672 · doi:10.3389/fnins.2024.1420601
What was done
This paper is a narrative review synthesizing pharmacological literature and proposed mechanisms regarding psilocybin and its active metabolite, psilocin, for the potential treatment of Alzheimer's disease. It examines mechanistic pathways such as 5-HT2A receptor modulation, management of neuropsychiatric symptoms, strategies to mitigate hallucinogenic adverse effects, and associated ethical and legal dimensions.
What was found
The abstract reports no quantitative trial data or effect estimates. It describes theoretical mechanisms including 5-HT2A receptor modulation leading to increased neural plasticity, reduced inflammation, improvements in specific cognitive domains (creativity, flexibility, emotional facial recognition), and potential alleviation of depression and anxiety in Alzheimer's disease patients.
Why it matters
Effective disease-modifying and symptomatic therapies for Alzheimer's disease remain limited, and this review outlines a mechanistic framework for considering psychedelic compounds like psilocybin as potential therapeutic candidates.
Limits
The abstract describes a narrative conceptual review rather than a systematic review or empirical clinical trial. No sample size, clinical trial outcomes, or quantitative safety and efficacy metrics in patients with Alzheimer's disease are provided.
Cited by
- context Psilocybin has not worked well for Alzheimer's disease because patients cannot remember their experience or trip.